- Home
- APLE vs ZLAB Comparison
APLE vs ZLAB Comparison
Compare APLE & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLE
- ZLAB
- Stock Information
- Founded
- APLE 2007
- ZLAB 2013
- Country
- APLE United States
- ZLAB China
- Employees
- APLE N/A
- ZLAB N/A
- Industry
- APLE Real Estate Investment Trusts
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- APLE Real Estate
- ZLAB Health Care
- Exchange
- APLE Nasdaq
- ZLAB Nasdaq
- Market Cap
- APLE 3.6B
- ZLAB 3.0B
- IPO Year
- APLE 2015
- ZLAB 2017
- Fundamental
- Price
- APLE $15.85
- ZLAB $26.95
- Analyst Decision
- APLE Buy
- ZLAB Strong Buy
- Analyst Count
- APLE 4
- ZLAB 4
- Target Price
- APLE $17.25
- ZLAB $52.50
- AVG Volume (30 Days)
- APLE 1.6M
- ZLAB 960.6K
- Earning Date
- APLE 11-04-2024
- ZLAB 11-12-2024
- Dividend Yield
- APLE 6.03%
- ZLAB N/A
- EPS Growth
- APLE 23.65
- ZLAB N/A
- EPS
- APLE 0.86
- ZLAB N/A
- Revenue
- APLE $1,410,888,000.00
- ZLAB $355,748,000.00
- Revenue This Year
- APLE N/A
- ZLAB $48.50
- Revenue Next Year
- APLE $2.34
- ZLAB $47.37
- P/E Ratio
- APLE $18.65
- ZLAB N/A
- Revenue Growth
- APLE 6.04
- ZLAB 35.01
- 52 Week Low
- APLE $13.60
- ZLAB $13.48
- 52 Week High
- APLE $17.42
- ZLAB $36.60
- Technical
- Relative Strength Index (RSI)
- APLE 52.41
- ZLAB 45.71
- Support Level
- APLE $15.92
- ZLAB $25.85
- Resistance Level
- APLE $16.29
- ZLAB $29.87
- Average True Range (ATR)
- APLE 0.24
- ZLAB 1.05
- MACD
- APLE -0.05
- ZLAB -0.18
- Stochastic Oscillator
- APLE 18.35
- ZLAB 21.98
About APLE Apple Hospitality REIT Inc.
Apple Hospitality REIT Inc is a real estate investment trust that invests in income-producing real estate, majorly in the lodging sector, in the United States. It chiefly invests in upscale service hotels. All of the company's hotels operate under the Marriott or Hilton brands. Apple Hospitality has wholly-owned taxable REIT subsidiaries, which lease all of the company's hotels from wholly-owned qualified REIT subsidiaries. These hotels are managed under separate agreements with various hotel management companies that are unaffiliated with Apple Hospitality. The company derives its income from hotel revenue, its sole segment.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.